country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-167828

Copy Link Print Information

ARN25062

Name: ARN25062
Brand: MedChemExpress
SKU: HY-167828
Price: 1098.00 USD
Availability: InStock
Rating: 5 (1 reviews)

ARN25062 (compound 27) is a CDC42/RHOJ inhibitor with antitumor activity. ARN25062 is a novel trisubstituted pyrimidine derivative.

For research use only. We do not sell to patients.

CAS No.: 3036492-85-7
Formula: C₂₂H₂₁F₃N₄
Molecular Weight:398.42

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (268 KB)

ARN25062 Chemical Structure

CAS No.: 3036492-85-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
Chemical Information
Protocols (1)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

ARN25062 (compound 27) is a CDC42/RHOJ inhibitor with antitumor activity. ARN25062 is a novel trisubstituted pyrimidine derivative^[1].

All Ras Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	5.1 μM Compound: 27; ARN25062	Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as reduction in cell viability incubated for overnight by CellTiter-Glo assay Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as reduction in cell viability incubated for overnight by CellTiter-Glo assay	[PMID: 37026468]
A-375	IC₅₀	5.1 μM Compound: ARN25062	Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant and activity RHOJ/CDC42 assessed as inhibition of cell growth incubated for overnight by CellTiterGlo assay Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant and activity RHOJ/CDC42 assessed as inhibition of cell growth incubated for overnight by CellTiterGlo assay	[PMID: 38866385]
SK-MEL-28	IC₅₀	6.1 μM Compound: 27; ARN25062	Antiproliferative activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for overnight by CellTiter-Glo assay Antiproliferative activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for overnight by CellTiter-Glo assay	[PMID: 37026468]
SK-MEL-28	IC₅₀	6.1 μM Compound: ARN25062	Antiproliferative activity against human SK-MEL-28 cells harboring BRAF V600E mutant and activity RHOJ/CDC42 assessed as inhibition of cell growth incubated for overnight by CellTiterGlo assay Antiproliferative activity against human SK-MEL-28 cells harboring BRAF V600E mutant and activity RHOJ/CDC42 assessed as inhibition of cell growth incubated for overnight by CellTiterGlo assay	[PMID: 38866385]
SK-MEL3	IC₅₀	4.6 μM Compound: 27; ARN25062	Antiproliferative activity against human SK-MEL3 cells harboring BRAF V600E mutant assessed as reduction in cell viability incubated for overnight by CellTiter-Glo assay Antiproliferative activity against human SK-MEL3 cells harboring BRAF V600E mutant assessed as reduction in cell viability incubated for overnight by CellTiter-Glo assay	[PMID: 37026468]
SK-MEL3	IC₅₀	4.6 μM Compound: ARN25062	Antiproliferative activity against human SK-MEL3 cells harboring BRAF V600E mutant and activity RHOJ/CDC42 assessed as inhibition of cell growth incubated for overnight by CellTiterGlo assay Antiproliferative activity against human SK-MEL3 cells harboring BRAF V600E mutant and activity RHOJ/CDC42 assessed as inhibition of cell growth incubated for overnight by CellTiterGlo assay	[PMID: 38866385]
SW480	IC₅₀	5.9 μM Compound: 27; ARN25062	Antiproliferative activity against human SW480 cells harboring KRAS G12V mutant assessed as reduction in cell viability incubated for overnight by CellTiter-Glo assay Antiproliferative activity against human SW480 cells harboring KRAS G12V mutant assessed as reduction in cell viability incubated for overnight by CellTiter-Glo assay	[PMID: 37026468]
SW480	IC₅₀	5.9 μM Compound: ARN25062	Antiproliferative activity against human SW480 cells harboring KRAS G12V mutant and activity RHOJ/CDC42 assessed as inhibition of cell growth incubated for overnight by CellTiterGlo assay Antiproliferative activity against human SW480 cells harboring KRAS G12V mutant and activity RHOJ/CDC42 assessed as inhibition of cell growth incubated for overnight by CellTiterGlo assay	[PMID: 38866385]

Chemical Information

CAS No. 3036492-85-7
Molecular Weight 398.42
Formula C₂₂H₂₁F₃N₄
SMILES

FC(F)(C1=CC(NC2=CC(C3=CC=CC=C3)=NC(C4CCNCC4)=N2)=CC=C1)F
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocols

All Animals and Diseases

Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (268 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Nicoletta Brindani, et al. Design, Synthesis, In Vitro and In Vivo Characterization of CDC42 GTPase Interaction Inhibitors for the Treatment of Cancer. J Med Chem. 2023 Apr 27;66(8):5981-6001. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote